TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00401024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03383731

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2
Description: the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
Study: NCT02771691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Group Therapy for Adolescents
Study: NCT01917773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study: NCT01341041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chlorine dioxide
Description: one time wash with 50ppm CD solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: one time wash with 50-100 cc normal saline
Study: NCT00694122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (glargine)
Description: Described in Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (glargine)
Description: Described in Arm Description
Study: NCT03768297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual zone concept
Description: immediate implant with bone fill till soft tissue level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual zone concept
Description: immediate implant with bone fill till soft tissue level
Study: NCT01710371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: 296 MBq (8 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Arginine Hydrochloride-R-Gene 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Arginine Hydrochloride-R-Gene 10
Study: NCT04693026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib oral tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab IV Infusion
Study: NCT01139424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic suturing
Description: endoscopic suturing of the anastomotic leak
Study: NCT03800810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Study: NCT04324489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Study: NCT01197027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: Standard HIV counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: Standard HIV counseling
Study: NCT04713995

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary recommendations
Description: Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
Study: NCT00086307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
Study: NCT03800810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Somatropin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Somatropin
Study: NCT02040636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: 0.5 ml, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: 0.5 ml, Intramuscular
Study: NCT02219113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Study: NCT00086307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
Study: NCT02219113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study: NCT03334266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN)
Description: The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.

Intervention type: OTHER
Group type: OTHER
Intervention: Injury Prevention Education (IPE)
Description: The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.

Intervention type: OTHER
Group type: OTHER
Intervention: Optimized Standard Care (OSC)
Description: OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Standard Care (OSC)
Description: OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
Study: NCT01127061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
Study: NCT04549987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure withchanging working archwire monthly
Description: Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
Study: NCT03926403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)
Description: Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)
Description: Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnosis techniques
Description: Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthesia
Description: Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
Study: NCT01817010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Component Rehabilitation (CMC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (CON)
Study: NCT03083912

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortimel Complete
Description: The residents included receive 2 bottle por day.
Study: NCT02956889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
Study: NCT02990884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study: NCT00321412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study: NCT02990884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study: NCT03450772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon® 25000
Description: Experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon® 10000
Description: Active comparator
Study: NCT00501319

Intervention type: BEHAVIORAL
Intervention: Interactive Voice Response (IVR)
Description: Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 20 minutes to complete.
Study: NCT04062955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan
Study: NCT00272779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovi-Emtricitabine (TDF/FTC) tablet
Description: One tablet with 300 mg - 200 mg once a day for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV
Description: 400 mg (3 133mg capsules) BID for 96 weeks
Study: NCT02086214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive pressure therapy
Description: Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
Study: NCT01665586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration
Study: NCT02526121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Volume of 400 mL every 3 weeks, 3 times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and lifestyle counseling.
Description: Dietary and lifestyle counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle counseling.
Description: Dietary and lifestyle counseling.
Study: NCT04527107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 1
Description: 3 intravitreal injections of THR-149 dose level 1, 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 2
Description: 3 intravitreal injections of THR-149 dose level 2, 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 3
Description: 3 intravitreal injections of THR-149 dose level 3, 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 0.13mg
Description: 3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 0.13mg + aflibercept 2mg
Description: 3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept 2mg + THR-149 0.13mg
Description: 3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2mg
Description: 3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
Study: NCT01566617

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care and Pharmaceutical care
Description: Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: These patients will only receive standard care, with out follow-up by the pharmacist
Study: NCT01416753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UCR
Description: BVM-based regulation of ultrafiltration and conductivity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UTR
Description: BVM-based regulation of ultrafiltration; regulation of temperature
Study: NCT00321412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-120
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study: NCT02836821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: apatinib was administered in the morning after an overnight fast of at least 10 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Capsules
Description: rifampicin was administered in the morning 2 hours after breakfast
Study: NCT04776226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Antidepressant use in patients with depression
Study: NCT02107456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling was performed for one week, three times a week.
Study: NCT01767363

Intervention type: OTHER
Intervention: 5-alpha reductase inhibitors
Description: Use of 5-alpha reductase inhibitors over the course of the study period.

Intervention type: OTHER
Intervention: 5-alpha reductase inhibitors
Description: Use of 5-alpha reductase inhibitors over the course of the study period.

Intervention type: OTHER
Intervention: Alpha-blockers
Description: Use of alpha-blockers over the study period.

Intervention type: OTHER
Intervention: Alpha-blockers
Description: Use of alpha-blockers over the study period.
Study: NCT03965286

Intervention type: DRUG
Intervention: DAAs
Description: Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
Study: NCT05457231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific feedback based on an in-depth assessment tool for communication skills training
Description: In addition to the specific feedback based on an in-depth assessment tool, four strategies modified from common strategies in the previous studies were incorporated into the intervention protocol, including lecture, patient interview, brief feedback, and self-reflection
Study: NCT06354894

Intervention type: DEVICE
Intervention: Proximal humeral fracture fixation
Description: percutaneous pinning VS plate and screws
Study: NCT03696745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous umbilical cord blood stem cells
Description: autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: 0.9% Sodium-chloride in control group
Study: NCT01247701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan dosing will be as follows: Patients \< 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \> 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients \> 10 kg: 40 mg/m\^2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Stem Cell Infusion
Description: The cord blood stem cells will be infused on Day 0.
Study: NCT03987191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Description: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT02219113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of autologous ADRC
Study: NCT03774498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne repair and protect
Description: NovaMin \& fluoride toothpaste
Study: NCT03987191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Description: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT03789994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective touch
Description: The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.

Intervention type: OTHER
Group type: OTHER
Intervention: Fine motor exercise
Description: Fine motor exercises that are commonly used for rehabilitation.
Study: NCT06187363

Intervention type: PROCEDURE
Intervention: Tubularized incised plate procedure
Description: Tubularized incised plate urethroplasty procedure

Intervention type: PROCEDURE
Intervention: Other procedures
Description: Other procedures than tubularized incised plate urethroplasty procedure
Study: NCT03832088

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: Berg Balance Scale performed for balance disorder

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test
Description: Timed Up and Go Test for walking speed
Study: NCT00834431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famvir® 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study: NCT04033276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immune globulin
Description: iv intravenous immune globulin
Study: NCT02732821

Intervention type: PROCEDURE
Intervention: Gastric Per Oral Endoscopic Myotomy
Description: Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.